00013

21.0402.05%
WS

Wei-Guo Su

CEO, Chief Scientific Officer & Executive Director (Leave of Absence)

Dr. Wei-Guo Su, B.Sc., Ph.D., has been the Chief Executive Officer of HUTCHMED (China) Limited since March 04, 2022. Dr. Su is currently on Leave of Absence. Dr. Su has been the Chief Scientific Officer and Executive Vice President of HUTCHMED (China) Limited (formerly known as Hutchison China MediTech Limited) since 2012 and as its Executive Director since March 27, 2017. He was Executive Vice President of HUTCHMED (China) Limited since 2012 until March 04, 2022. Dr. Su served as an Independent Director of Foxconn Technology Co., Ltd. since October 20, 2021 until May 31, 2024. Dr. Su served as a Senior Vice President of Drug Discovery at Hutchison MediPharma Limited. He joined Hutchison MediPharma in 2005, prior to which he spent years in U.S. R&D organization of Pfizer and served as its Director of the Medicinal Chemistry Department. Dr. Su delivered several high quality new drug candidates during his time with Pfizer with his last role being a Director in the Medicinal Chemistry Department. In March 2017, Dr. Su was granted the prestigious award by the China Pharmaceutical Innovation and Research Development Association (PhIRDA) as one of the Most In?uential Drug R&D Leaders in China. He holds Ph.D. and Post-doctoral Fellowship in Chemistry from Harvard University under the guidance of Nobel Laureate Professor E. J. Corey and his Bachelor's degree in Chemistry from Fudan University in Shanghai, China. He has Master of EMBA program from National Chengchi University.

Positions